Palisade Bio (NasdaqCM:PALI) Earnings Call Presentation

NASDAQ: PALI palisadebio.com Phase 1b in Fibrostenotic Crohn's Disease March 31, 2026 Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and pre-clinical and clinical development plans, expected near and long-term milestones, hypothesis related to PALI-2108, the potential of PALI-2108 to treat inflammatory bowel disease ("IBD"), our ability to successfully co ...